Filing Flows › Apyx Medical (APYX) › Guidance & outlook
Apyx Medical (APYX) guidance and outlook
Apyx Medical (APYX) lowered its guidance on Nov 5, 2026: Revenue $59.0M–$60.0M for FY2026; Gross margin 63%–65% for FY2026; Operating expenses $41.0M–$42.5M for FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $59.0M–$60.0M | reaffirmed |
| Revenue | FY2026 | $54.0M–$55.0M | new |
| Gross margin | FY2026 | 63%–65% | new |
| Operating expenses | FY2026 | $41.0M–$42.5M | lowered |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Apyx Medical's latest quarter
Apyx Medical, Q3 2026: revenue $14.0M (+9% year over year), operating margin -4.1%, net loss $1.8M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Apyx Medical raise or lower its guidance?
Apyx Medical (APYX) lowered its guidance on Nov 5, 2026: Revenue $59.0M–$60.0M for FY2026; Gross margin 63%–65% for FY2026; Operating expenses $41.0M–$42.5M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.